Cidara Therapeutics Stock Price - CDTX

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cidara Therapeutics Inc CDTX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.06 -2.27% 2.58 2.70 2.45 2.70 2.64 19:59:39
Bid Price Ask Price Spread Spread % News
2.31 2.79 0.48 17.2% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
697 133,131 $ 2.62 $ 349,245 199,546 1.2225 - 3.30
Last Trade Time Type Quantity Stock Price Currency
15:59:40 940 $ 2.58 USD

Cidara Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 85.24M 33.04M $ -59.02M -2.83 - 32.01M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cidara Therapeutics News

Loading Messages....

Latest CDTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CDTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.542.842.452.68224,8230.041.57%
1 Month2.432.842.192.47212,8890.156.17%
3 Months2.002.841.702.22170,6520.5829.0%
6 Months1.543.181.22252.15303,2821.0467.53%
1 Year2.983.301.22252.20217,196-0.40-13.42%
3 Years10.4011.751.22254.24152,751-7.82-75.19%
5 Years16.1119.131.22256.14123,160-13.53-83.99%

Cidara Therapeutics Description

Cidara Therapeutics Inc functions in the healthcare sector based in the United States. Its business involves the development of novel anti-infectives for the treatment of serious infections, especially caused due to fungus. The company's main drug constitutes echinocandins antifungals in the form of CD101IV and CD101 topical. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis. In addition, Cidara has developed a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious diseases.

Your Recent History
Cidara The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.